Picture EBD Group BioPharm America 2018 Boston September 600x60px
Organisation › Details

NewLink Genetics Corporation (Nasdaq: NLNK)

NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. Indoximod is being evaluated in combination with treatment regimens including anti-PD-1 agents, cancer vaccines, and chemotherapy across multiple indications such as melanoma, prostate cancer, acute myeloid leukemia, and pancreatic cancer. *


Period Start 1999-01-01 established
Products Industry cancer immunotherapy (immuno-oncology, I-O)
  Industry 2 IDO inhibitor
Person Person Link, Charles J., jr. (NewLink Genetics 201706 CEO)
  Street 2503 South Loop Drive
  City 50010 Ames, IA
  Tel +1-515-296-5555
    Address record changed: 2017-06-14
Basic data Employees C: 51 to 100 (2014-10-20)
    * Document for �About Section�: NewLink Genetics Corporation. (6/8/17). "Press Release: NewLink Genetics to Regain Rights to GDC-0919". Ames, IA.
Record changed: 2017-06-14


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for NewLink Genetics Corporation (Nasdaq: NLNK)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px

» top